The healthcare company has agreed to acquire a phase III-ready specialty medicine to treat a form of liver disease, expanding its pipeline of liver disease treatments.
The healthcare company's directors have acquired additional ordinary shares through the firm's employee share plan.
The biopharma company is ending the development of an anti-TIGIT monoclonal antibody after interim analyses showed the drug did not meet efficacy targets in phase 2 trials.
The healthcare company has granted its CEO a top-up conditional share award under the firm's performance share plan.
The healthcare company has announced a director's shareholding transaction.
The pharmaceutical company announced positive results from a phase III trial of its drug linerixibat for treating cholestatic pruritus in primary biliary cholangitis patients.
The healthcare company has announced the appointment of a new director to its board.
The pharmaceutical company reports positive results from a phase III trial of its Nucala drug in treating chronic obstructive pulmonary disease.
The major pharmaceutical company reported solid Q1 2025 results, with moderate revenue growth and strong cash generation. The firm reaffirmed its full-year guidance, signaling confidence in its performance.
The healthcare company has received UK regulatory approval for its Blenrep combinations to treat relapsed/refractory multiple myeloma, marking the first such approval globally.